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Abstract 
 
Background 
We report the development of a cutaneous melanoma risk algorithm based upon 7 
factors; hair colour, skin type, family history, freckling, nevus count, number of large 
nevi and history of sunburn, intended to form the basis of a self-assessment webtool 
for the general public.  
 
Methods 
Predicted odds of melanoma were estimated by analysing a pooled dataset from 16 
case-control studies using logistic random coefficients models. Risk categories were 
defined based on the distribution of the predicted odds in the controls from these 
studies. Imputation was used to estimate missing data in the pooled datasets. The 
30th, 60th and 90th centiles were used to distribute individuals into four risk groups 
for their age, sex and geographic location.  Cross-validation was used to test the 
robustness of the thresholds for each group by leaving out each study one by one.  
Performance of the model was assessed in an independent UK case-control study 
dataset.   
 
Results 
Cross-validation confirmed the robustness of the threshold estimates.  Cases and 
controls were well discriminated in the independent dataset (area under the curve 
0.75, 95% CI 0.73-0.78).  29% of cases were in the highest risk group compared with 
 6 
7% of controls, and 43% of controls were in the lowest risk group compared with 
13% of cases.  
  
Conclusion 
We have identified a composite score representing an estimate of relative risk and 
successfully validated this score in an independent dataset.   
 
Impact 
This score may be a useful tool to inform members of the public about their 
melanoma risk. 
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Introduction 
 
Cutaneous melanoma continues to increase in incidence in white populations, 
especially in Europe (1) . There is evidence of stabilization in incidence rates in 
some countries within Europe (in Lithuania, Estonia, Slovakia, Ireland and Scotland) 
and notably outside Europe, in Israel, Australia, New Zealand, the USA and Canada, 
showing a marked cohort effect (1).  The large increase in incidence over the past 50 
years and more recent stabilization of rates in several countries suggest that 
behavioural factors, probably related to sun exposure, underlie the cohort-based 
trends. These observations reinforce the view that change in sun-related behaviour 
remains a desirable aim for melanoma prevention(2).  
 
Red hair, freckling and skin reported to burn rather than tan are unequivocally 
associated with increased risk for melanoma in meta-analyses and pooled data 
analyses (3, 4). A more potent phenotypic risk factor is the presence of many 
melanocytic nevi and large (or clinically atypical) nevi, as confirmed by meta-
analyses (5) and pooled-data analyses (6). These phenotypes are strongly 
genetically determined, and genes associated both with nevus phenotype and 
pigmentation have been shown to be associated with melanoma risk in genome-
wide association studies (7). It is therefore not surprising that family history of 
melanoma, defined as melanoma in a first degree relative, also has been consistently 
identified as a risk factor (3). 
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Although these phenotypic risk factors are well described in the medical literature, 
it is important that the general public is able to extrapolate an understanding of 
their own risk from the existing published evidence. We constructed a risk tool to 
allow individuals to assess their lifetime risk of melanoma that will benefit both 
those at average as well as at increased risk relative to the underlying risk in their 
population, using variables that can be reliably self reported by members of the 
general public. The aim of this analysis was to construct this risk algorithm based on 
our previous pooled data analyses of melanoma case-control studies performed at 
different latitudes (4, 6) and then to test the algorithm in an independent UK 
melanoma case-control study (8, 9).    
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Materials and Methods 
We carried out a pooled data analysis of melanoma case-control data sets from 
studies conducted in Europe (temperate climate), North America (temperate and 
warmer climate), Australia and Hawaii (hotter climate) in the period 1979 to 1999.  
Previous analyses of these data are presented in two papers on sun-exposure 
patterns (4) and the nevus phenotype (6) associated with risk. These two papers 
comprehensively described the approaches taken to pooled data analysis.  Since our 
model is designed to underpin a risk tool for public usage, we considered only 
variables that were deemed self-reportable by members of the public, even though 
other variables had been shown to be significantly associated with risk of melanoma 
(e.g. solar keratoses) and our model may have had better predictive value with their 
inclusion.  Genetic data were excluded for the same reason. A summary is provided 
here. 
 
Data Collection 
 
Eligible studies were identified first as those reported in a systematic meta-analysis 
conducted by Gandini et al. containing analyses conducted prior to 2002 (3, 5, 10). 
Second, studies conducted between 2002 and 2007 were identified using a 
MEDLINE search.  Twenty-six studies met the inclusion criteria, and all authors who 
could be traced were invited to participate. The authors of sixteen studies 
participated.  The pooled dataset consisted of eight studies from Europe, five from 
North America, one from Hawaii and two from Australia. In each of these studies, 
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data had been collected on some or all of the following variables: nevus phenotype, 
hair color, sunburn history, Fitzpatrick skin type, freckling, family history of 
melanoma and age.  Data on eye colour were also collected but this variable was 
found to be highly correlated with hair colour and was dropped from the final model.   
The variables were grouped into categories where it was clear that this was 
appropriate (table 1). These variables were established risk factors for melanoma as 
described above (3, 5, 10), further details can be found in the supplementary 
information.  
 
 
Generating estimates for the effect of covariates used in the risk algorithm 
 
The pooled data were analysed using a logistic random coefficients model to account 
for heterogeneity between studies. Pooled odds ratios (OR) were estimated for the 
effect of each categorical variable on melanoma risk adjusted for the other six 
variables (table 1), age and sex using winBUGS (a more detailed explanation can be 
found in (6)).  The Western Canada study (Elwood et al. 1985) (11) was omitted 
from the final model as there were  no nevus count data available.     
 
Creating the risk score 
 ǲǳǡy multiplicatively combining the estimates in table 1. This 
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composite estimated odds ratio (OR) was considered the estimated relative risk of 
an individual developing melanoma compared with an individual from the same 
population who had the lowest possible risk (black hair, fewer nevi than half the 
population, had not been sunburnt, had no freckles, no large nevi, had a Fitzpatrick 
skin type of III or IV and had no family history of melanoma). 
 
Categorisation of risk and calculation of thresholds 
 
To provide more stable and interpretable risk estimates, we used controls from the 
pooled analysis as a sample of the combined population and generated an estimate 
of the background population distribution of the risk score. Table 2 lists each of the 
included studies.  Some variables were not recorded in all of the studies. In addition 
1.5% of all data were missing at the individual level for recorded variables. Missing 
data rates are described in supplementary table 1.  To calculate a risk score for 
individuals within these studies, we used imputation as described below to fill in the 
missing values.   
 
Imputation of missing data using Multiple Imputation by Chained Equations (MICE) 
 
We assumed that the data could be treated as missing at random (MAR) and 
implemented MICE to impute missing values ǲǳin R 3.0.2(12). 
We ran the imputation analysis in 30 chains over 15 iterations.  Ǯǯ
separate run of the analysis, with different random assignments of the missing data 
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points, upon which the imputation is performed independently of the chains. 
Further details of the imputation process can be found in the supplementary 
methods.  The composite melanoma risk score was computed for each individual in 
each chain and the results from each of the 30 chains were merged together into one 
composite dataset. We used the 30th, 60th and 90th centiles to distribute individuals 
into four risk groups; Low, relative to peers, Medium-Low, relative to peers, 
Medium-High, relative to peers and High, relative to peers.  Peers are defined as 
individuals of the same age and sex drawn from the same population. 
 
Attributable risk 
We calculated attributable risk using the cases in the Leeds case-control data set by 
imputed missing values as described above, calculating risk scores for each 
individual and applying the method of Bruzzi et al. (13). 
 
Robustness of thresholds 
 
We investigated the robustness of the threshold estimates by dropping each study in 
turn and recalculating the 20th, 30th, 40th, 50th, 60th, 80th and 90th centiles, using 
MICE to impute missing values as above. Large deviation from the threshold values 
computed using all data with data from a particular study omitted shows that the 
individual study has a large influence on the algorithm. 
 
Validation in independent data taken from the Leeds case-control study  
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To test the efficacy of the risk algorithm, we investigated its performance in data 
collected from 960 population-ascertained incident melanoma cases and 513 
controls recruited to a case-control study performed in Leeds, UK (8, 9).  Further 
details can be found in the supplementary information. Data on the variables used to 
build the risk tool were extracted from questionnaires and classified in the same 
manner as for the pooled data described above.  
 
Composite melanoma risk scores were calculated based on the phenotypic and 
environmental data recorded for these cases and controls.  A receiver operator 
curve (ROC) was constructed and the area under the curve (AUC) was estimated Ǯǯ(14).  95% confidence intervals were computed for the 
ROC curves using DeLongǯs method (15).  Cases and controls were also grouped into 
risk categories using the threshold estimates calculated from the pooled data, and a 
difference between the risk classification of cases and controls was tested using a 
chi-square test.  
 
Most users of a risk tool aimed at the public will not have access to professional 
assessment of mole counts and freckling.  We therefore assessed how using self-
reported mole counts and freckling scores affected the classification of cases in the 
Leeds controls. Further details of the methods used to do this can be found in the 
supplementary material. 
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Results 
 
Calculating the risk score 
 
The composite risk score based on the seven variables has a theoretical 
approximate range of 1 to 233 (table 1). This score is the combined odds of 
developing melanoma compared to the combined odds for a person in the lowest 
theoretical category of risk for someone of the same sex and age.  In the pooled data 
we observed the full range of theoretical risk score (1-233, supplementary figure 1).  
In the Leeds melanoma data we saw a reduced range of scores (1-188, 
supplementary figure 2).  
 
Risk categories 
 
Thresholds for the pre-defined risk categories derived from controls in the pooled 
data are shown in table 3.  Individuals are classified as being low risk  (< 3.32), 
medium-low risk (3.32-8.46), medium-high risk (8.46-32.80) or high risk ( ?32.80) 
relative to the background risk in the population. For example, a person with red 
hair, Fitzpatrick skin type I, freckling, but has no large nevi, a low nevus count, who 
has not been severely sunburnt and has no family history of melanoma in a first-
degree relative would have a risk score of 4.62 (1.76x1.66x1.58 from estimates in 
table 1) and would be categorized as ǲmedium-low risk, relative to peersǳ (using the 
thresholds in table 3).  
 15 
 
Testing the robustness of threshold estimates using Ǯleave-one-study-outǯ cross-
validation 
 
To test the robustness of the thresholds we removed each study in turn, performed 
MICE using the same settings on the remaining data, and then recalculated 
threshold values. Table 3 shows the results of omitting each study on the threshold 
values at 7 different points in the distribution. There was no evidence that omitting 
any of the studies caused gross distortion of the threshold values. 
 
Validation using the Leeds case-control data 
 
The risk score was computed for each individual in the Leeds case-control study as 
above.  Initially we used only complete cases to reduce the number of assumptions 
made about the data. ROC curve analysis showed that the raw composite score was 
capable of distinguishing cases from controls reasonably well  (AUC=0.75, 95% CI 
0.73-0.78 , figure 1). Cases and controls were also classified into four risk groups 
using the threshold values generated using the 30th, 60th and 90th centile values of 
the controls from the pooled data analysis.  The proportion of cases and controls 
that fall into each of the four risk groups is shown in table 4. Cases and controls 
were well separated (chi-squared test: p<2.2 x10-16); 29% of cases are in the highest 
risk group compared with 7% of controls, and 43% of controls are in the lowest risk 
group compared with 13% of cases.  However, the Leeds population had a greater 
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proportion of controls at ǲlow risk, relative to peersǳ compared to pooled controls, 
as in the latter the controls were by definition approximately distributed in the risk 
groups as 30%, 30%, 30% and 10%. 
 
Finally, we imputed missing data in the Leeds cohort using MICE and repeated the 
above analyses.  There was a small improvement in the model (AUC=0.77) but no 
difference in the distribution of controls (supplementary table 2). 
 
We estimated overall attributable risk from the Leeds dataset to be 87.8%. 
 
Agreement between self-reported and nurseǯ counts of moles 
 
We assessed the reliability of self-reported versus nurse-assessed mole counts and 
freckling in the Leeds control group. Supplementary figure 3 shows a Bland-Altman 
plot comparing self-reported counts of moles on the back with nurse counts of the 
back in the Leeds controls.  The mean difference between the two counts is 3 moles, 
and the 95% limits of agreement are wide (-23.5, 29.4). Larger discrepancies are 
seen for individuals as the average mole count increases; in the majority of these 
instances the patient has overestimated the number of moles on their back 
(difference > 0).  
 
Reasoning that laypersons might identify patterns of moles more accurately than 
individual moles, Leeds cohort participants were also asked which of four diagrams 
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best represented their mole count (supplementary figure 4).  Their responses were 
compared to the nurse-assessed mole counts grouped using the centile thresholds 
implemented in the risk model (0-50%, 51-75%, 75-90%, >90%). 37% of 
individuals classified themselves in the same nevus score rank as the nurses 
(supplementary table 3) even though the measures are not equivalent. Finally, there 
was agreement about the presence of any freckling in 63% of controls although the 
two variables are still highly significantly associated (supplementary table 4, chi-
squared test 3x10-5).   
 
With respect to risk classification in the pooled data, we compared how well 
individuals are classified when the self-reported counts or nurse counts are used 
(supplementary table 5) in both cases and controls.  A good correlation between the 
two sets of measurements is seen using the self-reported counts; 97% of individuals 
are classified within one rank of the nurse counts, and 57% are classified in exactly 
the same group.  However, there is a net improvement in the classification of cases 
into higher risk groups and controls into lower risk groups when the nurse counts 
are used (NRI=0.29); the majority of the improvement is due to increased 
classification of cases into higher risk groups (p(ranked higher | case) = 0.35).  We 
also compared the performance of the model using self-reported measures to the 
nurse reported measures using ROC curve analysis.  The discriminatory ability of 
the model is lower when self-reported mole counts are used (AUC=0.70, 95% CI 
0.66-0.73), which is similar to an alternative model where mole count and freckling 
were omitted (AUC=0.69, 95% CI 0.66-0.73).  
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Absolute risk 
While we have presented our model to produce categories of risk relative to the 
underlying population risk for someone of a similar age and sex, with some small 
modifications it is possible to produce absolute risk estimates as well. Using data 
taken from the Cancer Research UK and UK Office for National Statistics websites 
(16-18), it is possible to estimate that the absolute risk for a 30-year old woman 
from the UK with the risk factors discussed earlier would be approximately 0.04% 
over the next 5 years.  Further details can be found in the supplementary data. 
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Discussion 
The leveling off of melanoma incidence rates in some countries, continued rise in 
others, and the effects of birth cohort on incidence (1) all suggest modifiable 
environmental exposures may affect incidence.  There is strong evidence of effects 
of intermittent high exposure to the sun on melanoma risk (10). Therefore the need 
for melanoma prevention advice directed at sun protection is clear.  Our study was 
designed to construct a risk algorithm based upon large melanoma case-control data 
sets to enable members of the public to estimate their own risk relative to that of 
others in their population. Use of this algorithm to motivate change in sun-related 
behavior is based on the theory that primary prevention advice is more effective 
when the targeted persons believe themselves to be at relatively high risk; a study of 
modification of the behavior of adolescents in the sun has provided empirical 
support for this theory(19).  On the other hand, individuals who are told that they 
have relatively low risk may well decide that they can ignore sensible sun protection 
measures in the sun.   Any tailored risk measurements must avoid underplaying the 
dangers of risky behavior in the sun for all individuals.  
 
Other melanoma risk tools have been implemented previously for public use. The 
tool provided by the NCI (20, 21) gives an estimate of absolute risk and focuses 
exclusively on one population (the United States).  A recent study has similarly 
produced a model that predicts the absolute 5-year risk of melanoma for individuals 
in New Zealand but the authors recommend that external validation is performed 
before it is used for clinical practice(22).   The online risk tool produced by the New 
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South Wales Government(23) produces no final estimate of risk  but instead 
provides short explanations for why each question was asked to inform users of the 
risk factors.  The Harvard School of Public Health web-tool produces an estimate of 
risk that is relative to peers of the same age and sex for individuals over 40 (24).  
 
Eiser et al have previously suggested that numerical information may be interpreted 
as more exact than it is (25, 26).  The primary approach we have taken is to provide 
a classification of risk into categories relative to population risk, but we have also 
shown that our estimates can easily be used to produce an estimate of 10- or 5-year 
absolute risk by combining with local data. Similar classification systems to ours 
have been suggested in the past (27, 28). In one instance categorical groupings were 
used to assign rough estimates of 10-year risk(29).  We propose that our algorithm, 
which is based on data taken from multiple case-control studies worldwide, may be 
applicable to more than just one population, although as yet we have only tested it 
on one (Leeds, UK).  The distribution of controls in the Leeds study differs from that 
in the pooled case-control studies, and is weighted towards more controls being 
classified in lower risk groups.   
 
Conveying risk effectively is a difficult and complex issue (30) and beyond the scope 
of this paper to explore fully.  In practical applications of our risk tool, ideally both 
risk relative to the baseline population and estimates of absolute risks would be 
provided. We have demonstrated that it is easy to adapt our model to output 
absolute risks, given appropriate local data on melanoma incidence and overall 
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mortality rates, although more sophisticated methods may be required to account 
for geographical variation in incidence rates in larger countries such as the USA(21). 
 
The beneficial effects of sun exposure include higher vitamin D levels, which are 
essential for bone health and might be important for many other aspects of health, 
such as prevention of cancer (31) and diseases associated with the metabolic 
syndrome (32) although this has not been proven. It may therefore be sub-optimal 
to recommend very high levels of sun protection for individuals at lower risk of 
melanoma, especially in temperate climates, where there is less sunshine. This 
project had the second aim of assisting members of the public to identify themselves 
as at lower risk than their peers, so that advice on sun avoidance could be better 
tailored to the individual.   The data sets were built almost entirely from data from 
white-skinned individuals as they are the population most affected by melanoma. 
The incidence of melanoma in black and Asian populations is much lower, and likely 
our algorithm would not be applicable to these populations. 
 
A weakness of the study is that the risk algorithm was built and tested using case- 
control data.  Consequently, the odds ratios that the risk score is built upon are 
potentially subject to the biases inherent to case-control designs, such as recall bias, 
selection bias, participation bias, and/or confounding.   We have also made an 
assumption that since the odds ratio estimates for each factor used to build the risk 
score were derived from a multivariable joint analysis, they can be treated as 
independent and therefore can be combined multiplicatively.  We have not 
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accounted for potential interactions between factors in this model.  Interactions are 
notoriously difficult to show, and a model that included all potential interactions 
between the factors would contain too many variables to be practical. A strength of 
the study is that the data sets used were very large and detailed. As with all pooled 
data sets, the data are from disparate studies. Reassuringly, however, in the 
previously reported analyses the estimates of relative risk of melanoma in relation 
to sunburn (4) and nevus phenotype were remarkably consistent across all the 
studies (6). The point estimates of the odds of melanoma for an individual are highly 
imprecise, particularly at the extremes of the distribution.  Therefore we have taken 
the approach of categorizing risk into broad groups.   
 
A challenging aspect of this analysis was that several variables were not recorded in 
all studies; this was addressed by imputation using MICE.  Of particular concern is 
the large mole variable, which is only available for 7 of the 16 studies and is defined 
differently in different studies (e.g. large moles were defined by a research nurse as 
>8mm in Kanetsky 2001 but self-reported  ? 5mm in LeMarchand 2006). However 
we did not see much perturbation in the threshold scores when each study was 
dropped in turn. 
 
The analyses carried out resulted in a composite score representing an estimate of 
relative risk for individuals compared with those with the lowest level of risk factors.  
The AUC in the ROC analysis was 0.75, suggesting that the measure explained a 
substantial proportion of the risk.  Recently Vuong et al. identified 28 melanoma 
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prediction models generated from 19 studies published before April 2013, in which 
discrimination ranged from an AUC of 0.62 to 0.86(33) so our model is competitive 
in this regard.  It is likely that we could have increased the AUC if we had used 
additional variables such as genetic factors.  However, we hope ultimately to 
provide a tool that will be used by individuals reporting their own risk factors. 
Therefore, it was practical to use simple measures that can be self-reported.  
 
We generated 4 different risk groups based upon a distribution of risk estimates in 
the controls using the 30th, 60th and 90th centiles as cut-points.  Cases and controls 
were well differentiated.  Approximately 7% of controls in the Leeds data were 
found in the highest risk group compared with 29% of cases.  
 
We have shown evidence that risk prediction is more accurate when professionally 
measured freckling and mole count variables are used.  This may be a potential 
weakness for developing a risk tool using this algorithm, as the results may be 
misleading in the presence of misclassification. Nonetheless the majority of 
individuals were classified in the same group irrespective of whether self-reported 
or professionally derived variables were used.  For a risk tool aimed at the public it 
may be best to leave out these variables as there was evidence that models that 
omitted the self-reported variables lost no discriminatory power.  However there 
was a substantial improvement in classification when professionally derived 
variables were used, particularly for ranking cases in higher risk groups, so ideally 
these variables should be incorporated in some form.  We made a strong assumption 
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that the qualitative groups in the diagrams match well to the equivalent centile 
groups in the risk tool.  However there is substantial variation in mole count 
distributions between populations so this assumption may well be violated. 
Diagrams which better matched users to the four quantile groups would 
presumably perform better; this argues for the need to tailor self-estimation of nevi 
to each individual population if diagrams are to be used.  
 
In summary we have generated an algorithm for use in white populations to predict 
risk of melanoma. Practical application of this algorithm to general use in the future 
will require several more steps including validation in other cohorts from other 
regions to test its generalisability.  We hope to continue to refine the algorithm as 
additional data sets become available in low latitude and high latitude regions.  
Using simple measures, the algorithm can be used to help identify higher and lower 
risk individuals, relative to others of the same age and sex within a population, for 
whom the hazards of sun exposure would be different, and to produce estimates of 
absolute risk when combined with population-specific data.  
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Table 1:  Odds ratios for melanoma from a multivariable logistic random 
coefficients model including these factors, adjusted for age, sex, effect of study 
assessed in a pooled analysis of 15 case-control studies. 
Risk factor OR (95% CI)**  
n= 12387 n 
Hair color   
Brown/Black 1 7704 
Red 1.76 (1.41, 2.16) 3608 
Blond 1.41 (1.19, 1.67) 942 
   
Skin type   
III+IV 1 7508 
I+II 1.66 (1.36, 2.01) 3666 
   
Freckling   
No 1 5129 
Yes 1.58 (1.25, 2.01) 5050 
   
Family history of melanoma   
No 1 9054 
Yes 1.74 (1.21, 2.46) 614 
   
Total body nevus count distribution*   
0-50% 1 1354 
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50-75% 1.64 (1.12, 2.30) 638 
75-90% 2.72 (1.89, 3.81) 794 
>90% 5.50 (3.73, 7.89) 701 
   
Large nevi on body ȋ ? ?Ȍ   
None 1 1851 
1-2 2.26 (1.29, 3.68) 1041  ? ? 4.10 (2.19, 7.08) 712 
 
   Ș   
No 1 3080 
Yes 1.28 (1.05, 1.27) 6070 
 
* Nevus count was ranked within each study and classified into four centile groups 
(0-50%, 50-75%, 75-90%, >90%).  Nevus count is an age-dependent variable, so 
centile groups were generated separately for the under 50 and 50 and over age 
groups in each study and then combined as one variable  
 ** Risk score odds ratios are combined multiplicatively.  For example, an individual 
with black hair, skin type III, no freckling or family history of melanoma, but with a 
high nevus count including at least 3 large nevi and previous history of a serious 
sunburn would have a score of 28.9 (5.50x4.10x1.28)    
 Ș instances of sunburn ǯ 
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Table 2.  Variables present in each study used in the Multiple Imputation by Chained Equations (MICE) imputation. 
Study Hair 
colour 
Skin 
type 
Freckling Family 
history 
Total nevus 
count 
Large nevi Sunburn Others 
Bataille 1996(34) Yes Yes Yes Yes Body+Arms Arms Yes Atypical nevi 
Berwick 1996(35) Yes Yes Yes Yes Arms No Yes Raised nevi 
Elwood 1985(11) Yes Yes No* Yes No No Yes at 15 None 
Elwood 1990(36)  Yes Yes Yes No Arms Arms Yes None 
 Green 1985(37)  Yes Yes Yes Yes Arms No Yes None 
 Holly 1995(38) Yes Yes Yes Yes No Body Yes None 
 Holman 1984(39) Yes Yes No Yes Arms No Yes Raised nevi 
 Kanetsky 
2001(40) 
Yes Yes Yes Yes Body Body Yes Atypical nevi 
 Kennedy 2003(41) Yes Yes Yes No Body No Yes Atypical nevi 
LeMarchand 2006 
(42)  
Yes Yes Yes Yes Body+ArmsȘ Body+Arms Yes at 15 Raised nevi 
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Mössner 2007(43)   Yes Yes No No Arms No No None 
Osterlind 
1988(44)   
Yes Yes Yes Yes No Arms Yes at 15 Raised nevi 
Swerdlow 
1986(45) 
Yes Yes No Yes Body+Arms Body Yes at 20 None 
Titus-Ernstoff 
2005(46) 
Yes Yes Yes Yes Body+Arms No Yes Atypical nevi 
Westerdahl 
1994(47) 
Yes No Yes No Arms No Yes Raised nevi 
Westerdahl 
2000(48) 
Yes Yes Yes Yes Arms No Yes Raised nevi 
Ș Trained interviewers counted moles on the arms, moles on the body were self-counted. 
* Freckling data was collected but not used due to freckling being assessed retrospectively to adolescence in this study.
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Table 3:  Sensitivity analysis.  Estimates of threshold values omitting each study in 
turn.  For each row the data from the indicated study is omitted and the risk score 
thresholds are calculated based on the data in the other 15 studies. 
Study Omitted   Centile   
 20% 30% 40% 50% 60% 80% 90% 
Bataille 1996(34) 2.25 3.38 4.74 6.15 8.60 20.41 34.15 
Berwick 1996(35) 2.02 2.87 3.65 5.25 7.04 15.84 28.00 
Elwood 1985(11) 2.13 3.04 4.30 5.81 7.87 18.86 32.03 
Elwood 1990(36)  2.02 2.89 3.72 5.50 7.50 17.65 29.48 
 Green 1985(37)  2.14 2.94 4.10 5.54 8.25 20.27 34.21 
 Holly 1995(38) 2.14 2.91 3.77 5.50 7.63 17.65 29.48 
 Holman 1984(39) 2.26 3.38 4.83 6.86 9.71 22.55 35.70 
 Kanetsky 2001(40) 2.24 3.04 4.56 5.88 8.29 19.44 32.25 
 Kennedy 2003(41) 2.10 2.89 3.75 5.50 7.81 18.58 32.47 
LeMarchand 2006 (42)  2.26 3.38 4.80 6.49 9.13 22.03 35.63 
Mössner 2007(43)   2.10 2.91 3.90 5.50 7.87 17.78 32.02 
Osterlind 1988(44)   2.24 3.32 4.57 5.94 8.34 19.31 32.02 
Swerdlow 1986(45) 2.14 3.04 4.57 5.94 8.61 20.69 35.63 
Titus-Ernstoff 2005(46) 2.14 2.89 3.77 5.50 7.81 18.66 32.03 
Westerdahl 1994(47) 2.14 3.32 4.57 6.15 8.69 21.88 35.63 
Westerdahl 2000(48) 2.24 3.32 4.74 6.45 8.76 22.55 35.63 
NONEȘ 2.24 3.32 4.57 5.94 8.46 19.66 32.80 
  35 
ȘIndividuals are classified into the Low, Medium-Low, Medium-High and High 
groups based on the 30th, 60th and 90th percentiles. 
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Table 4: Number and percentage of cases and controls in each risk band for the 
Leeds datasetȘ.  
 
 Case (%) Control (%) Pooled 
controls* (%) 
Low, relative to 
peers** 
93 (13) 181 (43) 128 (30) 
Medium-Low, 
relative to peers 
160 (22) 137 (32) 128 (30) 
Medium-High, 
relative to peers 
265 (36) 77 (18) 128 (30) 
High, 
Relative to peers 
213 (29) 30 (7) 43 (10) 
  
*Expectation of how controls in the Leeds case-control data would be distributed if 
they followed the distribution pattern of the controls in the pooled analyses. 
** Peers are defined as individuals of the same age and sex drawn from the same 
population. Ș ? ?Ǥ ? ? ?-16 
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Figure legend 
 
Figure 1  ROC curve showing discrimination between cases and controls in the 
Leeds melanoma  case-control study using the risk algorithm: (AUC=0.75, 95% CI 
0.73-0.78). 
